Tuesday, August 09, 2016 8:45:47 AM
Currently, GW Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:
GW Pharma reported a narrower-than-expected loss in the third quarter of fiscal 2016. Our consensus called for a loss of $1.73 per share and the company reported a loss of 73 cents.
Revenues:
However, revenues fell short of expectations. GW Pharma posted revenues of $3.1 million, compared to our consensus estimate of $3.4 million.Key Stats: GW Pharma expects to seek FDA approval for Epidiolex for both Dravet syndrome and LGS indications in the first half of fiscal 2017.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM